BrightGene Bio Medical Technology C (688166) - Total Liabilities

Latest as of June 2025: CN¥2.80 Billion CNY ≈ $409.38 Million USD

Based on the latest financial reports, BrightGene Bio Medical Technology C (688166) has total liabilities worth CN¥2.80 Billion CNY (≈ $409.38 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 688166 operating cash flow to assess how effectively this company generates cash.

BrightGene Bio Medical Technology C - Total Liabilities Trend (2016–2024)

This chart illustrates how BrightGene Bio Medical Technology C's total liabilities have evolved over time, based on quarterly financial data. Check BrightGene Bio Medical Technology C liquid asset ratio to evaluate the company's liquid asset resilience ratio.

BrightGene Bio Medical Technology C Competitors by Total Liabilities

The table below lists competitors of BrightGene Bio Medical Technology C ranked by their total liabilities.

Company	Country	Total Liabilities
Zhejiang Dingli Mach Co Ltd SHG:603338	China	CN¥5.93 Billion
Cenergy Holdings SA BR:CENER	Belgium	€1.72 Billion
Victoria's Secret & Co NYSE:VSCO	USA	$4.45 Billion
Endeavour Group Ltd AU:EDV	Australia	AU$7.90 Billion
Jushri Technologies Inc Class A SHE:300762	China	CN¥1.48 Billion
Munters Group AB ST:MTRS	Sweden	Skr14.86 Billion
Nordstrom Inc NYSE:JWN	USA	$7.83 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down BrightGene Bio Medical Technology C's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of BrightGene Bio Medical Technology C.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.13	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.52	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BrightGene Bio Medical Technology C's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BrightGene Bio Medical Technology C (2016–2024)

The table below shows the annual total liabilities of BrightGene Bio Medical Technology C from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥2.73 Billion ≈ $399.04 Million	+4.31%
2023-12-31	CN¥2.61 Billion ≈ $382.55 Million	+8.05%
2022-12-31	CN¥2.42 Billion ≈ $354.06 Million	+97.04%
2021-12-31	CN¥1.23 Billion ≈ $179.69 Million	+210.70%
2020-12-31	CN¥395.23 Million ≈ $57.83 Million	+265.24%
2019-12-31	CN¥108.21 Million ≈ $15.83 Million	+2.55%
2018-12-31	CN¥105.52 Million ≈ $15.44 Million	+33.76%
2017-12-31	CN¥78.89 Million ≈ $11.54 Million	-51.91%
2016-12-31	CN¥164.05 Million ≈ $24.01 Million	--

About BrightGene Bio Medical Technology C

SHG:688166 China Biotechnology

Market Cap

$4.13 Billion

CN¥28.24 Billion CNY

Market Cap Rank

#4097 Global

#710 in China

Share Price

CN¥66.74

Change (1 day)

+5.77%

52-Week Range

CN¥40.25 - CN¥116.49

All Time High

CN¥116.49